Boehringer Ingelheim Hellas S.A. - Greece
| Държава: | Гърция |
| Кратка информация: | Value through Innovation is our Corporate Vision The Boehringer Ingelheim group of companies´ objectives and believes can be summed up in a single phrase: Value through Innovation, the central concept of our corporate vision. Together with our corporate culture concept "Lead & Learn", this vision is the driver of our corporate culture. A new vision for a new world Our corporate vision - "Value through Innovation": The objectives and beliefs of Boehringer Ingelheim can be summed up in a single phrase: Value through Innovation. This vision has helped us to build on our strengths and make the most of our distinctive character. In a competitive and fast-changing world, the value of products, services and companies is constantly changing. Real customer value today can only be created by constantly developing new solutions and doing what we already do better. Lead & Learn: The present phase in our evolution is Lead & Learn. Since 2004, it outlines ways in which Boehringer Ingelheim realises and delivers Value through Innovation. As our corporate culture, Lead & Learn is about all the people at Boehringer Ingelheim and how they work together. A new vision for the corporate culture: Lead & Learn superseded the concept of Vision & Leadership that was established in 1993 by the Shareholders and the Board of Managing Directors of the Boehringer Ingelheim corporation. The Vision, created for Boehringer Ingelheim worldwide, was built around the corporate vision of Value through Innovation. Since then, our corporate culture always was guided by this vision. A worldwide group of companies Boehringer Ingelheim is a worldwide operating affiliated group of companies with 42,224 employees. Get an overview of the organisation structure and our two main business areas: Human Pharmaceuticals and Animal Health. Our business areas Our Human Pharmaceuticals business area covers the segments Prescription Medicines Consumer Health Care Biopharmaceuticals Operations (Pharma Production and Chemical Production) In Animal Health, our core business segments serve food-producing and companion animals. Overview companies Boehringer Ingelheim companies In 1993, the Shareholders and the Board of Managing Directors of the Boehringer Ingelheim Corporation formulated a vision for Boehringer Ingelheim worldwide, built around the central concept of our Corporate vision "Value through Innovation". The history of Boehringer Ingelheim: A tradition of innovation The pharmaceutical company Boehringer Ingelheim was founded in 1885 by Albert Boehringer (1861-1939) in Ingelheim am Rhein. The pharmaceutical company Boehringer Ingelheim was founded in 1885 by Albert Boehringer (1861-1939) in Ingelheim am Rhein. From its beginnings in 1885 when it employed just 28 people in Nieder-Ingelheim, the company has since become a global enterprise. As part of research and development activities for innovative drugs, the company focuses primarily on the therapeutic areas of cardiovascular disease, respiratory diseases, diseases of the central nervous system, metabolic diseases, virological diseases and oncology. Historical timeline of Boehringer Ingelheim Production of lactic acid begins. 1885 – 1948: Innovative beginnings In 1885, Albert Boehringer purchased a small tartar factory in the Rhine-Hessian village of Nieder-Ingelheim. On 31 July, his company was included in the commercial register as “Albert Böhringer, chem. Fabrik vom 1. Aug. 1885 ab”. This laid the foundation for the present-day company Boehringer Ingelheim. He initially employed 28 people to manufacture tartaric acid salts used by pharmacies and dyeing works. Demand for this product surged in the first few years as fizzy lemonade and baking powder became popular. In 1893, Boehringer made the ground-breaking discovery that lactic acid can be produced in mass quantities by means of bacteria, a discovery that saw the company pioneer large-scale "biotech" production. Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield 1948 – 1988: Going global Following the death of Albert Boehringer (1861 - 1939), his two sons Albert jr. (1891-1960) and Ernst Boehringer (1896-1965) as well as his son-in-law Julius Liebrecht (1891-1974) took over this family company. They recognised the importance of international markets for chemical-pharmaceutical companies. A home-based subsidiary was established in 1946 in Biberach an der Riss when the Thomae production unit was added to Boehringer Ingelheim’s two existing plants. The first foreign subsidiary, which was established in Vienna in 1948, was followed by more subsidiaries in Europe and overseas. Value through Innovation 1988 – 2010: Value through innovation Following the death of Hubertus Liebrecht (1991), the owning family made some fundamental decisions regarding the company’s alignment. This was in response to changing global healthcare standards and the increasing cost of healthcare, and was designed to maintain the company’s leading position as a research-based pharmaceutical company. The corporate vision "Value through Innovation” is promoted and becomes firmly rooted in the company. This vision defines the targets and framework for the future of the company and represents the global leitmotif and orientation framework. |
| Сайт: | http://www.boehringer-ingelheim.com/ |
